Back to search results
NCT06660264

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

Enrolling by Invitation
NAAges 18+InterventionalHealth services
University of Pittsburgh
~600 participants
Updated 2025-10-30 on ClinicalTrials.gov
What's tested:Pharmacist Personalized Medication Review (PMR)Discussion of Pharmacogenomic results during the PMR

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Total Per Member Per Month (PMPM) Healthcare Costs
Measured over From 12 Months prior to PMR visit and from the PMR visit to 12 Months after the PMR visit

Conditions

Pharmacogenetics
Pharmacogenomic Drug Interaction

Explore related trials

PolypharmacyRisk for Adverse Drug ReactionsPharmacogenomic panel

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Philip E Empey, PharmD, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\>/= 18 years old
Enrolled in the UPMC insurance plan for at least 1 year
Identified by UPMC Healthplan as a Pitt/UPMC employee who is likely to benefit from preemptive PGx panel testing based on polypharmacy, high annual prescription costs and a risk for poor medication-related outcomes based on exposure to medications with FDA or CPIC Level A/B PGx guidance using payer data
Participating in Pitt+Me Discovery with elective return of PGx results

Exclusion

Previous panel PGx testing (self-reported)
Have a terminal illness (specifically metastatic cancer, palliative care or hospice)
Have had a liver, small bowel, or allogenic bone marrow/stem cell transplant
Cannot provide informed consent and/or complete the study protocol due to serious cognitive impairment
Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility)
Plan to drop UPMC Health Plan coverage for any reason within 12 months of enrollment
Recent blood transfusion may be exclusionary only if the end of recruitment is nearing and there is insufficient time to observe a minimum waiting period between date of transfusion and date of sample collection. These minimum waiting periods are determined by type of transfusion: 7 days for platelets/plasma/cryoprecipitate; 2 months for packed red blood cells (PRBCs): and 6 months for whole blood or unknown type of transfusion. Although a transfusion is unlikely to have major effects on genotype results from a saliva sample, these time windows remove this concern.

What this trial measures

  • Change in Total Per Member Per Month (PMPM) Healthcare CostsFrom 12 Months prior to PMR visit and from the PMR visit to 12 Months after the PMR visit

    Change in participant total per member/per month (PMPM) healthcare costs using healthplan claims data from 12 months prior to the pharmacist Personalized Medication Review (PMR) visit to 12 months after the PMR visit.